{"id":"NCT01054573","sponsor":"Janssen Infectious Diseases BVBA","briefTitle":"VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo","officialTitle":"An Open-label, Single-arm, Roll-over Trial of Telaprevir in Combination With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) for Subjects From the Control Group of the VX- 950-TiDP24-C216 Trial Who Failed Therapy for Virologic Reasons","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04","primaryCompletion":"2012-03","completion":"2012-05","firstPosted":"2010-01-22","resultsPosted":"2013-04-19","lastUpdate":"2013-05-08"},"enrollment":90,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"Telaprevir","otherNames":[]},{"type":"DRUG","name":"pegylated interferon (Peg-IFN) alfa-2a","otherNames":[]},{"type":"DRUG","name":"ribavirin (RBV)","otherNames":[]}],"arms":[{"label":"Telaprevir + Standard Treatment","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to provide access to telaprevir for patients from the control group in the C216 study, who failed treatment for virologic reasons. Efficacy, safety and tolerability of telaprevir in combination with standard treatment will be evaluated.","primaryOutcome":{"measure":"The Percentage of Participants Achieving a Sustained Virologic Response (SVR) 24 Weeks After the Last Dose of Study Drug (SVR24 Actual)","timeFrame":"End of trial (24 weeks after last dose, administerd at 48 weeks)","effectByArm":[{"arm":"Phase 3: T12(Q8h)/PR - Prior Null Responder","deltaMin":34.4,"sd":null},{"arm":"Phase 3: T12(Q8h)/PR - Prior Partial Responder","deltaMin":72.7,"sd":null},{"arm":"Phase 3: T12(Q8h)/PR - Prior Relapser","deltaMin":81.5,"sd":null},{"arm":"Phase 1: T12(Q8h)/PR","deltaMin":44.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":48,"countries":["United States","Australia","Belgium","Brazil","Canada","France","Germany","Israel","Netherlands","Poland","Puerto Rico","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["25712364"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":["Fatigue","Pruritus","Anaemia","Nausea","Headache"]}}